The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Journal club

[2026 update] Journal club: FLOW and the renal composite, component by component

N
NLoughranTL3Regular24 Dec 2025#1

Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did.

I have seen SUSTAIN 6 (N Engl J Med, 2016) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

0 likes 7mo
BT
baseline_tableTL2Member24 Apr 2026#2

the opening post is right about the mechanism and I think understates the practical bit.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

23 likes 3mo
AC
a.coelhoTL2 Moderator19 Jul 2026 · edited#3
baseline_table, post #2: the opening post is right about the mechanism and I think understates the practical bit. I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong… Go to post

Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available?

7 likes in reply to #2 9d

Suggested topics

TopicParticipantsRepliesViewsActivity
Second pass at: Journal club: LEADER as the historical anchor
Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with SURPASS-2 ( N…
MGJICLAIDO+75 81 2k 2y
Journal club: STEP-HFpEF and symptom endpoints
Journal club: STEP-HFpEF and symptom endpoints — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and finding…
MREPAKTWJD+18 22 2.5k 11mo
Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold?
The question in the title: Journal club: SUSTAIN 6 and its retinopathy signal — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen SURMOUNT-2 ( Lancet ,…
RONSPPSDOB+60 66 12k 16mo
Journal club: how we handle discontinuation in obesity trials
On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
LSCLPM 2 1.9k 12mo
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold?
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J Med ,…
BDBEMVD 3 28k 6mo

Related topics — sharing the tags journal club, randomised trial, estimand

TopicParticipantsRepliesViewsActivity
Cagrilintide molecular characteristics and analytical considerations
Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of a claim I…
KDPOARNSJH 4 41k 12mo
Coming back to: Sample size calculations, read backwards from the published number
On the subject in the title: Sample size calculations, read backwards from the published number Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
PRIEBMMTV+82 88 1.8k 11mo
What the GIP component of tirzepatide is thought to contribute, and how confident we can be
What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl…
EFVRCIAKOF+16 20 23k 19h
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit?
Revisiting: Is there a ceiling dose beyond which semaglutide stops adding benefit? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…
AWBWCEPLEK+5 9 30k 8d
Hepatic effects of glucagon receptor agonism: the mechanistic worry
Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024). Please read…
TOIOOID+51 56 700 22mo